Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

ArQule Articles

Daiichi Sankyo returns rights to ArQule for global AKT program

3 April 2013

Another disappointment with Daiichi Sankyo and ArQule's tivantinib

14 January 2013

ArQule and Daiichi Sankyo drop tivantinib trial in NSCLC

3 October 2012

Daiichi Sankyo to license ARQ 092 from ArQule, under joint AKIP research collaboration

11 November 2011

Kyowa Hakko Kirin starts Ph III trial of ARQ 197 (tivantinib) in NSCLC patients in Asia

10 August 2011

Daiichi Sankyo launches flu drug Inavir inhaler in Japan; expands deal with ArQule; gets favorable patent ruling against Lupin

20 October 2010

ArQule and Daiichi Sankyo move NSCLC drug ARQ 197 into Phase III clinical trial plan

4 August 2010

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS